Ospemifene use in postmenopausal women

Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi, Ranuccio Nuti

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists. These drugs have been intensively studied over the past decades and have proven to be a highly versatile group for the treatment of different conditions associated with menopause, including hormone-responsive cancer and osteoporosis. However, currently available SERMS are also responsible for side effects such as thromboembolic disorders, or gynecological symptoms (especially vaginal dryness and hot flushes). Objective/methods: The purpose of this article is to review the clinical trials of ospemifene, a new SERM in Phase III development for the treatment of vulvar and vaginal atrophy. The medical literature was reviewed for appropriate articles containing the terms 'ospemifene' and 'SERMs'. Results/conclusions: The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant. Ospemifene also appeared to be well tolerated, with few patients experiencing side effects. The additional positive results on bone and the breast observed in preclinical studies need to be clinically confirmed to extend the therapeutic potential of this new SERM.

Original languageEnglish
Pages (from-to)839-849
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Selective Estrogen Receptor Modulators
Atrophy
Estrogen Antagonists
Lubricants
Menopause
Estrogen Receptors
Osteoporosis
Breast
Therapeutics
Clinical Trials
Hormones
Bone and Bones
Ospemifene
Pharmaceutical Preparations
Neoplasms

Keywords

  • Estrogen
  • Menopause
  • Ospemifene
  • Osteoporosis
  • SERM
  • Vaginal atrophy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Gennari, L., Merlotti, D., Valleggi, F., & Nuti, R. (2009). Ospemifene use in postmenopausal women. Expert Opinion on Investigational Drugs, 18(6), 839-849. https://doi.org/10.1517/13543780902953715

Ospemifene use in postmenopausal women. / Gennari, Luigi; Merlotti, Daniela; Valleggi, Fabrizio; Nuti, Ranuccio.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 6, 06.2009, p. 839-849.

Research output: Contribution to journalArticle

Gennari, L, Merlotti, D, Valleggi, F & Nuti, R 2009, 'Ospemifene use in postmenopausal women', Expert Opinion on Investigational Drugs, vol. 18, no. 6, pp. 839-849. https://doi.org/10.1517/13543780902953715
Gennari, Luigi ; Merlotti, Daniela ; Valleggi, Fabrizio ; Nuti, Ranuccio. / Ospemifene use in postmenopausal women. In: Expert Opinion on Investigational Drugs. 2009 ; Vol. 18, No. 6. pp. 839-849.
@article{4a7509d40c4246e9bdeaf0c0dcc18a55,
title = "Ospemifene use in postmenopausal women",
abstract = "Background: Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists. These drugs have been intensively studied over the past decades and have proven to be a highly versatile group for the treatment of different conditions associated with menopause, including hormone-responsive cancer and osteoporosis. However, currently available SERMS are also responsible for side effects such as thromboembolic disorders, or gynecological symptoms (especially vaginal dryness and hot flushes). Objective/methods: The purpose of this article is to review the clinical trials of ospemifene, a new SERM in Phase III development for the treatment of vulvar and vaginal atrophy. The medical literature was reviewed for appropriate articles containing the terms 'ospemifene' and 'SERMs'. Results/conclusions: The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant. Ospemifene also appeared to be well tolerated, with few patients experiencing side effects. The additional positive results on bone and the breast observed in preclinical studies need to be clinically confirmed to extend the therapeutic potential of this new SERM.",
keywords = "Estrogen, Menopause, Ospemifene, Osteoporosis, SERM, Vaginal atrophy",
author = "Luigi Gennari and Daniela Merlotti and Fabrizio Valleggi and Ranuccio Nuti",
year = "2009",
month = "6",
doi = "10.1517/13543780902953715",
language = "English",
volume = "18",
pages = "839--849",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Ospemifene use in postmenopausal women

AU - Gennari, Luigi

AU - Merlotti, Daniela

AU - Valleggi, Fabrizio

AU - Nuti, Ranuccio

PY - 2009/6

Y1 - 2009/6

N2 - Background: Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists. These drugs have been intensively studied over the past decades and have proven to be a highly versatile group for the treatment of different conditions associated with menopause, including hormone-responsive cancer and osteoporosis. However, currently available SERMS are also responsible for side effects such as thromboembolic disorders, or gynecological symptoms (especially vaginal dryness and hot flushes). Objective/methods: The purpose of this article is to review the clinical trials of ospemifene, a new SERM in Phase III development for the treatment of vulvar and vaginal atrophy. The medical literature was reviewed for appropriate articles containing the terms 'ospemifene' and 'SERMs'. Results/conclusions: The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant. Ospemifene also appeared to be well tolerated, with few patients experiencing side effects. The additional positive results on bone and the breast observed in preclinical studies need to be clinically confirmed to extend the therapeutic potential of this new SERM.

AB - Background: Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists. These drugs have been intensively studied over the past decades and have proven to be a highly versatile group for the treatment of different conditions associated with menopause, including hormone-responsive cancer and osteoporosis. However, currently available SERMS are also responsible for side effects such as thromboembolic disorders, or gynecological symptoms (especially vaginal dryness and hot flushes). Objective/methods: The purpose of this article is to review the clinical trials of ospemifene, a new SERM in Phase III development for the treatment of vulvar and vaginal atrophy. The medical literature was reviewed for appropriate articles containing the terms 'ospemifene' and 'SERMs'. Results/conclusions: The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant. Ospemifene also appeared to be well tolerated, with few patients experiencing side effects. The additional positive results on bone and the breast observed in preclinical studies need to be clinically confirmed to extend the therapeutic potential of this new SERM.

KW - Estrogen

KW - Menopause

KW - Ospemifene

KW - Osteoporosis

KW - SERM

KW - Vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=67649595194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649595194&partnerID=8YFLogxK

U2 - 10.1517/13543780902953715

DO - 10.1517/13543780902953715

M3 - Article

VL - 18

SP - 839

EP - 849

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 6

ER -